Page 5 - Tenax Therapeutic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tenax therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tenax Therapeutic Today - Breaking & Trending Today

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

New U.S. patent provides intellectual property (IP) protection until December 2040, and may qualify for term extension beyond 2040 ....

United States , Chris Giordano , Tenax Therapeutics Inc , Orion Corporation , Trademark Office , Tenax Therapeutics , United States Patent , Chief Executive Officer , Chief Medical Officer , Scientific Advisory Board , North American , Tenax Therapeutic Phase , Tenax Therapeutic ,

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United States , Chris Giordano , John Mullaly , Nasdaq Stock Market , Tenax Therapeutics Inc , Lifesci Advisors , Orion Corporation , Trademark Office , Tenax Therapeutics , United States Patent , Chief Executive Officer , Chief Medical Officer , Scientific Advisory Board , North American , Tenax Therapeutic Phase , Tenax Therapeutic , Sci Advisors ,

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in PH-HFpEF

There are currently no FDA approved treatments for PH-HFpEF, a condition affecting more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030 ....

United States , Chris Giordano , Orion Corporation , Tenax Therapeutics Inc , Trademark Office , Tenax Therapeutics , United States Patent , Chief Executive Officer , Stuart Rich , Chief Medical Officer , North American , Tenax Therapeutic Phase , Tenax Therapeutic ,

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Once granted, this patent will provide intellectual property protection until December 2040, and may qualify for additional U.S. patent term extension beyond 2040 There are currently no FDA approved. | May 31, 2023 ....

United States , Chris Giordano , John Mullaly , Lifesci Advisors , Tenax Therapeutics Inc , Orion Corporation , Trademark Office , Globenewswire Inc , Nasdaq Stock Market , United States Patent , Chief Executive Officer , Chief Medical Officer , North American , Tenax Therapeutic Phase , Tenax Therapeutic , Sci Advisors , Tenax Therapeutics , Nc Stock Exchange , Press Release , Da Tenx Us88032l5066 ,

Tenax Therapeutics Achieves Major Milestone as USPTO Grants

Once granted, this patent will provide intellectual property protection until December 2040, and may qualify for additional U.S. patent term extension. ....

United States , Chris Giordano , John Mullaly , Tenax Therapeutics Inc , Lifesci Advisors , Nasdaq Stock Market , Orion Corporation , Trademark Office , United States Patent , Chief Executive Officer , Stuart Rich , Chief Medical Officer , Tenax Therapeutics , North American , Tenax Therapeutic Phase , Tenax Therapeutic , Sci Advisors , Nasdaq Tenx , Tenax Therapeutics ,